Capital Fund Management (CFM)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-18,644
Closed -$792K 1611
2020
Q3
$792K Sell
18,644
-29,728
-61% -$1.3M 0.01% 931
2020
Q2
$2.32M Sell
48,372
-28,138
-37% -$1.4M 0.04% 457
2020
Q1
$3.52M Buy
76,510
+28,016
+58% +$1.41M 0.05% 375
2019
Q4
$2.91M Buy
48,494
+36,459
+303% +$2.17M 0.02% 725
2019
Q3
$681K Buy
+12,035
New +$677K 0.01% 1140
2018
Q2
Sell
-14,258
Closed -$751K 2336
2018
Q1
$751K Sell
14,258
-34,589
-71% -$2.01M ﹤0.01% 1328
2017
Q4
$2.61M Sell
48,847
-76,683
-61% -$4.27M 0.01% 884
2017
Q3
$7.49M Buy
125,530
+66,284
+112% +$4.01M 0.05% 412
2017
Q2
$4.67M Buy
59,246
+9,900
+20% +$810K 0.04% 484
2017
Q1
$4.09M Buy
+49,346
New +$3.67M 0.03% 547
2016
Q4
Sell
-82,415
Closed -$5.77M 1904
2016
Q3
$5.77M Buy
+82,415
New +$4.57M 0.05% 419

Other funds holding EGRX

Capital Fund Management (CFM)'s EGRX Position: Q4 2020 in Review

Capital Fund Management (CFM) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 18,644 shares — an estimated $792K sold.

Capital Fund Management (CFM) first reported a position in EGRX in Q3 2016 and held it in 11 quarters. The position peaked at $7.49M in Q3 2017. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Capital Fund Management (CFM) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 18,644 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $792K.
  • Capital Fund Management (CFM) first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 11 quarters.
  • Capital Fund Management (CFM)'s Eagle Pharmaceuticals, Inc. position peaked at $7.49M in Q3 2017.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2020, filed 12 Feb 2021.